Verrucarin A in cancer therapy

Pancreatic cancer (ductal pancreatic adenocarcinoma / PDA) is one of the most difficult cancers to treat. Common chemotherapeutic agents often only bring about a short-term improvement in symptoms and, unfortunately, experience has shown that they have little effect on the patient’s recovery. New types of therapy are urgently needed here. 

This is where Verrucarin A comes into play. Trichothecenes are mycotoxins that inhibit protein synthesis and cause ribotoxic stress reactions in mammalian cells. Verrucarin A (VC-A) is a type D macrocyclic mycotoxin. It inhibits cell proliferation and causes apoptosis in breast cancer cells. 

Verrucarin A and its potent anti-tumor activity

Verrucarin A also affects PDA cells. Strong anti-tumor activity is observed here. Verrucarin A strongly inhibits proliferation and blocks cells in the S phase. Blocking the progression of the cell cycle goes hand in hand with the inhibition of the cell cycle regulatory proteins cyclin D1, cyclin E, cyclin-dependent kinases (cdks) cdk2, cdk4 and cdk inhibitor WAF1 / 21. 

Verrucarin A causes apoptosis in PDA cells, as shown by the increased annexin V-FITC binding, cleavage of poly (ADP-ribose) polymerase 1 (PARP-1) and procaspases-3, -8 and -9. VC-A also causes mitochondrial depolarization and release of cytochrome c and inhibits proteins of the Bcl-2 family that regulate apoptosis (Bcl-2, Bcl-xL, Bax and Bad). 

Verrucarin A reduces apoptosis inhibitors

Verrucarin A also reduces the apoptosis inhibitors survivin and c-IAP-2. It downregulates the expression of prosurvival phospho-Akt (p-Akt), core factor κB (NF-κB) (p65) and mammalian target of rapamycin (p-mTOR) signaling proteins and their downstream mediators. 

In conclusion, it can be said: The research results show a strong antiproliferative and apoptosis-inducing activity of verrucarin A for PDA cells due to the arrest of the cell cycle and inhibition of the prosurvival (anti-apoptotic) AKT / NF-κB / mTOR signal. 

We offer Verrucarin A in bulk quantities and look forward to your inquiry – whether by phone or directly via our contact form. 

Photo: Creative commons – Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0)

More news


Meet us in Milan

Our Head of Pharma, Michael Schaeffler, will be attending this year's CPhI and looks forward to meeting customers and partners in person.

Would you like to meet him at the event?...

Read more